Top 83%
dans ce catalogue (1041 pratiques notées)
Les scores se concentrent dans le haut de l’échelle ; la position au sein du catalogue est donc souvent plus parlante que le chiffre seul.
Evidence of impact / measured results2/3
Multiple independent evaluations exist (Manchester Institute 2017, the Connell review 2015, a UKRI-commissioned 2022 study), giving genuine evidence coverage, though the findings themselves are mixed: a positive GBP2.4-per-GBP1 benefit ratio alongside documented weak commercialisation outcomes.
Transferability / demonstrated replication2/3
Modelled on the US SBIR and applied across many UK public bodies (NHS, MOD, DEFRA and others), with the NHS's SBRI Healthcare sub-programme showing the mechanism transfers across sectors.
Scalability1/3
The 2015 Connell review found funding had fallen to GBP63M (a 25% YoY drop) and that roughly 85% of contracts were below the minimum size needed for meaningful benefit, indicating scaling limits.
Sustainability / continuity2/3
Operating in some form since 2001 and still active today as 'Contracts for Innovation' despite a documented mid-2010s funding decline, showing institutional persistence through setbacks.
Innovation1/3
The demand-side, procurement-funded R&D contract mechanism was adapted from the pre-existing US SBIR model rather than newly invented in the UK.
Inclusiveness / equity1/3
Roughly half of applicants are concentrated in southern England per the Cambridge Industrial Innovation Policy group's data, indicating a documented regional imbalance in who benefits.
Multi-stakeholder collaboration2/3
Delivered by Innovate UK/UKRI on behalf of multiple distinct public bodies (NHS, Ministry of Defence, DEFRA and others), reflecting real cross-government coordination, though the 2022 evaluation found departmental ownership still uneven.
Evidoria. SBRI — L'Initiative Britannique de Recherche pour les Petites Entreprises, Révisée et Relancée à Deux Reprises. ID persistant: 5c982a46-9285-4b49-9981-ea328752374d.